Home Cart Sign in  
Chemical Structure| 355025-24-0 Chemical Structure| 355025-24-0

Structure of Ki16425
CAS No.: 355025-24-0

Chemical Structure| 355025-24-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.

Synonyms: Debio 0719

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ki16425

CAS No. :355025-24-0
Formula : C23H23ClN2O5S
M.W : 474.96
SMILES Code : O=C(O)CCSCC1=CC=C(C2=C(NC(OC(C3=CC=CC=C3Cl)C)=O)C(C)=NO2)C=C1
Synonyms :
Debio 0719
MDL No. :MFCD06798341
InChI Key :LLIFMNUXGDHTRO-UHFFFAOYSA-N
Pubchem ID :10367662

Safety of Ki16425

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ki16425

GPCR

Isoform Comparison

Biological Activity

Target
  • LPA2

    LPA2, Ki:6.5 μM

  • LPA1

    LPA1, Ki:0.34 μM

  • LPA3

    LPA3, Ki:0.93 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
PC-3M-luc-C6 cells 1 µM 12 hours Ki16425 completely inhibited LPA-induced migration of PC-3M-luc-C6 cells PMC4119209
cardiomyocytes 1 µM 1-5 days To evaluate the effect of LPA on cardiomyocyte proliferation, results showed that LPA induced cardiomyocyte proliferation in a time- and concentration-dependent manner PMC7532668
786-O cells 1 μM 30 minutes Ki16425 effectively attenuated LPA-induced cell signaling and invasion PMC4191899
UMRC3 cells 1 μM 30 minutes Ki16425 effectively attenuated LPA-induced cell signaling and invasion PMC4191899
cardiomyocytes 1, 5, 10 µM 48 hours To evaluate the effect of different concentrations of LPA on cardiomyocyte proliferation, results showed that LPA increased the number of EdU-positive cardiomyocytes in a concentration-dependent manner PMC7532668
human primary valve interstitial cells 1 µM 7 days Ki16425 negated platelet-induced mineralization of VIC cultures PMC6492053
Valve interstitial cells (VICs) 10 µM 7 days Ki16425 prevented OxLDL-induced mineralization of VICs PMC5852522
Mouse Embryo Fibroblast (MEF) 10 μM Ki16425 completely blocked AOCP-induced MEF cell migration, indicating that LPA is the major component in AOCP responsible for inducing MEF cell migration. PMC2679274
4T1 cells 60 nM Debio-0719 had little antiproliferative effect on 4T1 cells but inhibited their motility. PMC3611817
MDA-MB-231T cells 60 nM Debio-0719 inhibited the migration ability of MDA-MB-231T cells. PMC3611817
MDA-BO2/GFP cells 0-10 µM Ki16425 dose-dependently inhibited LPA-induced proliferation of MDA-BO2/GFP cells. PMC1480460
CHO/H92523wt cells 0-10 µM Ki16425 dose-dependently inhibited LPA-induced proliferation of CHO/H92523wt cells. PMC1480460

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LDLR-/-apoB100/100IGFII transgenic mice intraperitoneal injection 5 mg/kg/day once daily for 5 weeks Ki16425 abrogated platelet-induced progression of aortic valve calcification PMC6492053
SD rats myocardial infarction model intraperitoneal injection 20 mg/kg daily from the day of birth To evaluate the effect of Ki16425 on cardiomyocyte proliferation, results showed that Ki16425 significantly reduced the number of pH3-, BrdU- and Ki67-positive cardiomyocytes PMC7532668
Mouse LPA-induced hydrocephalus model Intracranial injection 1 mg/kg Single injection, 15 minutes before LPA injection Pretreatment with Ki16425 resulted in 44% of animals exhibiting no VM, but this reduction was not statistically significant from controls. PMC6785248
BALB/c Nude mice RCC xenograft models subcutaneously 20 mg/kg once daily for 48 days Ki16425 markedly inhibited RCC tumor growth and reduced tumor proliferation and angiogenesis PMC4191899
Mice LDLR-/-/ApoB100/100/IGFII transgenic mice Intraperitoneal injection 5 mg/kg/day Once daily for 3 months Ki16425 reduced the progression rate of CAVS and decreased hydroxyapatite deposition in aortic valve leaflets PMC5852522
Mice 4T1 spontaneous metastasis model Subcutaneous injection 15 mg/kg Twice daily, continued until the end of the experiment Debio-0719 significantly inhibited the metastasis of 4T1 cells to the liver and lungs but had no effect on primary tumor size. PMC3611817
NMRI nu/nu mice Breast cancer bone metastasis model Subcutaneous injection 20 mg/kg Once daily for 16 days Ki16425 significantly inhibited the progression of bone metastasis, reducing bone destruction and tumor burden. PMC1480460
Mice Experimental Autoimmune Encephalomyelitis (EAE) model Intraperitoneal injection 15 and 30 mg/kg Once daily until the end of the experiment Ki16425 significantly deteriorated motor disability in EAE mice, increased spinal cord demyelination, inflammation, cellular infiltration, and blood-brain barrier disruption. The underlying mechanism was associated with the overproduction of reactive oxygen species (ROS) via NOX2 and NOX3. PMC8527776

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.53mL

2.11mL

1.05mL

21.05mL

4.21mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories